Utility and Performance of Heart Transplant Test Confirmed
|
By LabMedica International staff writers Posted on 24 Jun 2015 |
|
Image: Histopathology of interstitial edema in a cardiac transplant biopsy may be a sign of antibody-mediated rejection (Photo courtesy of the Society for Cardiovascular Pathology).
An innovative molecular blood test has been used following a heart transplant procedure and this test enables routine, noninvasive surveillance of acute cellular rejection, thereby assisting clinicians in the care and management of patients.
New uses of the test have been described, specifically, the combination of the test with the measure of donor-specific cell-free DNA which improves the performance of the test, or an analysis of correlations between test scores and long-term outcome for patients, which could give a new predictive role to the test.
In the Cardiac Allograft Rejection Gene Expression Observational II (CARGO II) prospective, observational, multicenter clinical study blood samples for testing were collected during post-transplant surveillance visits, beginning at least 55 days after heart transplantation, with or without cardiac biopsy. After analyzing the samples, the test result was provided as a unique score ranging from 0 to 40, with high values indicating a greater risk of acute cellular rejection.
Moderate to severe acute cellular rejection (i.e., histopathology analysis of biopsies showing a grade greater than or equal to 3A according to the International Society for Heart and Lung Transplantation grading system) were reported by pathologists in 106 out of 3,324 biopsies (3.2%), in 79 out of 594 patients (13.0%). Taking into account these observations, the study shows that the negative predictive value of AlloMap (DIAXONHIT; Paris, France) is greater or equal to 99.0% for AlloMap scores less than 34. This threshold is therefore associated with a low risk of moderate to severe acute cellular heart graft rejection.
Loïc Maurel, MD, President of the Management Board of DIAXONHIT, said, “With a central laboratory becoming operational soon in Strasbourg, France, DIAXONHIT will be able to duplicate the testing practice already conducted by CareDx (Brisbane, CA, USA) in the US, and provide AlloMap testing to European patients for whom the performance of the test was confirmed in the CARGO II study. The results that were presented during the second joint symposium at this year’s International Society for Heart and Lung Transplantation congress organized by DIAXONHIT and CareDx are quite encouraging, as they confirm a more routine use of the test in several US centers and already present potential new uses of AlloMap that should further benefit heart transplant patients.”
Related Links:
DIAXONHIT
CareDx
New uses of the test have been described, specifically, the combination of the test with the measure of donor-specific cell-free DNA which improves the performance of the test, or an analysis of correlations between test scores and long-term outcome for patients, which could give a new predictive role to the test.
In the Cardiac Allograft Rejection Gene Expression Observational II (CARGO II) prospective, observational, multicenter clinical study blood samples for testing were collected during post-transplant surveillance visits, beginning at least 55 days after heart transplantation, with or without cardiac biopsy. After analyzing the samples, the test result was provided as a unique score ranging from 0 to 40, with high values indicating a greater risk of acute cellular rejection.
Moderate to severe acute cellular rejection (i.e., histopathology analysis of biopsies showing a grade greater than or equal to 3A according to the International Society for Heart and Lung Transplantation grading system) were reported by pathologists in 106 out of 3,324 biopsies (3.2%), in 79 out of 594 patients (13.0%). Taking into account these observations, the study shows that the negative predictive value of AlloMap (DIAXONHIT; Paris, France) is greater or equal to 99.0% for AlloMap scores less than 34. This threshold is therefore associated with a low risk of moderate to severe acute cellular heart graft rejection.
Loïc Maurel, MD, President of the Management Board of DIAXONHIT, said, “With a central laboratory becoming operational soon in Strasbourg, France, DIAXONHIT will be able to duplicate the testing practice already conducted by CareDx (Brisbane, CA, USA) in the US, and provide AlloMap testing to European patients for whom the performance of the test was confirmed in the CARGO II study. The results that were presented during the second joint symposium at this year’s International Society for Heart and Lung Transplantation congress organized by DIAXONHIT and CareDx are quite encouraging, as they confirm a more routine use of the test in several US centers and already present potential new uses of AlloMap that should further benefit heart transplant patients.”
Related Links:
DIAXONHIT
CareDx
New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Hemoglobin Testing System
VARIANTnbs
Latest Molecular Diagnostics News
- Four-In-One Molecular Test Detects and Differentiates Among Most Prevalent Respiratory Viruses in 20 Minutes
- First-Line PSA Testing More Cost-Effective Than First-Line MRI for Prostate Cancer Screening
- Proteomics Platform Identifies Proteins in Blood to Give Cancer Warning 7 Years before Diagnosis
- AI Technology-Based Blood Test Identifies Lung Cancer Earlier
- Ultra-Sensitive Blood Test Predicts Breast Cancer Recurrence Months or Even Years before Relapse
- Prenatal Testing Offers Window for Finding Mother’s Cancer Risk
- New Molecular Test Detects More Cervical Cancer Cases
- New Panel Quickly and Accurately Identifies 16 Common Gastrointestinal Pathogens
- New DNA Testing Method Offers Faster and More Accurate Pathogen Identification
- Precise Cancer Detection Method as Quick and Easy as Blood Test
- DNA Spit Test More Accurate At Identifying Future Prostate Cancer Risk
- Novel Method Combining Nano Informatics and AI Paves Way for Cancer Blood Tests
- Groundbreaking Molecular Diagnostic Kit to Provide Lyme Disease Detection in Minutes
- New Assay Detects Heart Failure Biomarker in Less than 11 Minutes
- Innovative Test Improves Assessment of Patients with Mild Traumatic Brain Injury
- New Method for Lung Microbiomes Analysis Predicts Mortality in Children after Bone Marrow Transplant
Channels
Clinical Chemistry
view channel
New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more
3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more.jpg "Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)")
POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more
Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
The conventional methods for measuring free cortisol, the body's stress hormone, from blood or saliva are quite demanding and require sample processing. The most common method, therefore, involves collecting... Read moreHematology
view channel
Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more
First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
Arboviruses represent an emerging global health threat, exacerbated by climate change and increased international travel that is facilitating their spread across new regions. Chikungunya, dengue, West... Read more
POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read moreImmunology
view channel.jpg "Image: The AI tool predicts whether someone’s cancer will respond to immune checkpoint inhibitors (Photo courtesy of National Cancer Institute)")
AI Tool Predicts Cancer Patients’ Response to Immunotherapy
Immune checkpoint inhibitors are a form of immunotherapy drug that enables immune cells to target and destroy cancer cells. At present, the Food and Drug Administration has approved two predictive biomarkers... Read more
Molecular Profiling Improves Diagnosis for Children with High Risk Cancers
Cancer remains the leading cause of disease-related death among children in most developed nations, and approximately one-fourth of these patients are diagnosed with aggressive, high-risk, or relapsed... Read more
.jpg "Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)")
Microbiology
view channel
POC STI Test Shortens Time from ED Arrival to Test Results
In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2.5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics... Read more
Integrated Solution Ushers New Era of Automated Tuberculosis Testing
Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
Sepsis affects up to 50 million people globally each year, with bacteraemia, formerly known as blood poisoning, being a major cause. In the United States alone, approximately two million individuals are... Read more
Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read morePathology
view channel
New WHO Reporting System for Lung Cytopathology to Enhance Diagnostic Accuracy
Lung cancer continues to be the most common cause of cancer-related deaths worldwide and ranks as the second most frequently diagnosed cancer in both men and women. The role of lung cytopathology, which... Read more
Self-Taught AI Tool Diagnoses and Predicts Severity of Common Lung Cancer
A computer program powered by artificial intelligence (AI) and trained on nearly half a million tissue images can effectively diagnose cases of adenocarcinoma, the most prevalent type of lung cancer.... Read more
Novel AI-Powered Method for Tissue Analysis Improves Understanding of Disease Pathology
Scientists at Brown University (Providence, RI, USA) and the University of Michigan (Ann Arbor, MI, USA) have created a groundbreaking computational technique to examine complex tissue data, potentially... Read more
Technology
view channel
Microneedle Patch Detects Skin Cancer Early
Wearable bioelectronics has emerged as a significant innovation in healthcare, especially in the field of biosensing, providing a new method to monitor individual health for both diagnostic and therapeutic purposes.... Read more
New Diagnostic System Achieves PCR Testing Accuracy
While PCR tests are the gold standard of accuracy for virology testing, they come with limitations such as complexity, the need for skilled lab operators, and longer result times. They also require complex... Read more
Industry
view channel
Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing
Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
Unlike severe traumatic brain injury (TBI), mild TBI often does not show clear correlations with abnormalities detected through head computed tomography (CT) scans. Consequently, there is a pressing need... Read more
Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
Beckman Coulter Diagnostics (Brea, CA, USA) and MeMed BV (Haifa, Israel) have expanded their host immune response diagnostics partnership. Beckman Coulter is now an authorized distributor of the MeMed... Read more_1.jpg "Image: Thermo Fisher will distribute Bio-Techne products across Europe (Photo courtesy of 123RF)")
